Future clinical perspectives. A concluding discussion.
Since there are considerable differences between animal models and human malignancies, new test systems are required for selecting effective antitumor drugs, such as T cell-deprived or nude mice, capable of hosting human tumor xenografts. Study of target determinants of drug action in normal and malignant cells is a promising approach for selecting proper drugs. In order to accomplish this task, cell separation techniques have to be further developed. Samples of human malignant cells need to be identified by morphological, biochemical and genetical markers. Clinicians face the problem of treating tumors individually. Malignant cells in leukemias and metastatic fluids can be successfully analyzed in respect of their drug sensitivity. It is expected that in the case of solid tumors similar attempts will result in a more rational therapeutic approach as well.